Preview Newsletter
XARELTO Media Monitoring – Week of 02-05-16
-
Xarelto Lawsuit Study Published By BMJ Indicates Possible Twofold Increased Risk Of GI Bleeds
Feb 1, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on studies published in the British Medical Journal which link the use of anticoagulant Xarelto to an increased risk for specific dangerous bleeding events, such as spontaneous vitreous hemorrhages (eye bleeds) and gastrointestinal bleeds. As lawsuit numbers surrounding the drug continue to increase on a regular basis, and the concerns of the plaintiffs involved have been made public, people across the nation are beginning to discuss some very serious side effects which have now been connected to the drug by multiple tests. -
A Silent Killer: Raise Your Blood Clot Awareness to Reduce Your Risks
Feb 1, 2016 | HealthNewsDigest.com
By Quentin Danziger
There are numerous situations which could cause you to develop a blood clot and sometimes it is not a lack of awareness but negligence that leads to this serious or fatal situation developing. If you have been affected and feel there is a claim to pursue, you can find xarelto lawsuit information at xlawsuit.com. -
Xarelto Lawsuit Plaintiffs Gain Support From JAMA Ophthalmology Study Results Linking Drug To Dangerous Bleeds
Feb 1, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerhelp.com reports on several studies pointing to data that appears to support plaintiffs arguments and raise more questions over the safety of new-generation anticoagulant drug Xarelto. The blood thinner is manufactured by Bayer Healthcare and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation). These new studies highlight a potential link to spontaneous and severe bleeding episodes, including stomach bleeds and eye-hemorrhages for patients using Xarelto. -
Xarelto Lawsuit Claims Drug Manufacturers Hold Liability For Wife’s Life-Threatening Injuries
Feb 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit which was filed against manufacturers Bayer AG and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson corporation). The lawsuit, filed by a couple from Ohio, alleges that their anticoagulant drug, Xarelto, caused the wife to suffer dangerous, life-threatening internal bleeding injuries. Together, the husband and wife have requested more than $150,000 compensation to help with their current medical bills, future medical bills, and pain and suffering. -
Xarelto Lawsuit Surge Creates Public Concern Over Blood Thinner’s Once-Daily Dosage
Feb 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an especially notable lawsuit filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer Healthcare in a Pennsylvania State Court. This lawsuit is important to observe because thousands of Xarelto lawsuits have been filed against these manufacturers regarding the uncontrollable bleeding dangers associated with the anticoagulant, however, this one brings up a new concern: the one pill per day dosage of the the new-generation blood thinner. -
Xarelto Lawsuit Plaintiffs Watch As Clinical Trials On Drug Spur Investigation Of European Regulators
Feb 2, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an investigation reviewing clinical trials of Xarelto by European regulators. This investigation follows a surge of lawsuits which have been filed against the blood thinner’s manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation). The plaintiffs involved in these mounting lawsuits commonly allege that use of the new-generation blood thinner can cause consumers increased risks of dangerous uncontrollable bleeding events. -
Xarelto Lawsuit Plaintiffs Are Encouraged By Similarities To Previously Settled Pradaxa Cases
Feb 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on similarities between today’s Xarelto lawsuits and previously settled Pradaxa lawsuits, which bring comfort to plaintiffs awaiting Xarelto trials and seeking what they consider to be justice. Xarelto lawsuit numbers continue to regularly increase as the many cases await trial. All Xarelto cases filed in federal courts from across the nation were consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML). These cases now make up MDL No. 2592 in New Orleans, and are said to involve over 2,800 lawsuits. -
Louisiana Xarelto Lawsuit Claims Anticoagulant Caused Fatal Bleeding and Subsequent Death of Grandmother
Feb 3, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) in relation to the blood-thinning drug they manufacture, Xarelto. The lawsuit was filed by a granddaughter on behalf of her grandmother who died after suffering health complications while taking Xarelto. She was prescribed the drug by her physician in September of 2014 to treat her deep vein thrombosis (DVT) condition. Only two months later, however, she suddenly suffered an intracranial bleed. Doctors termed the bleed as “irreversible and fatal,” and it ultimately cost the woman her life. -
Xarelto Lawsuit Numbers Now Surpass 3,000 Across The United States And Share Concerning Allegations
Feb 3, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on recent Xarelto lawsuit news, which indicates that cases filed against Janssen Pharmaceuticals and Bayer AG in relation to blood-thinning drug Xarelto have now surpassed 3,000 in number. A group of over 2,800 Xarelto lawsuits has been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592 in Louisiana while another group of 550 Xarelto lawsuits has been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania to form a mass tort group. -
Xarelto Lawsuit Plaintiffs Note Bellwether Trial Preparations In Louisiana MDL Number 2592
Feb 3, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the bellwether trial preparations of over 2,800 federally-filed Xarelto lawsuits which were consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592. The lawsuits which have been consolidated name the same defendants and commonly allege that Xarelto puts users at increased risk for dangerous uncontrollable bleeding episodes, which, in some cases, plaintiffs claim have been fatal. These cases continue to progress toward trial dates at this time and are centralized in the U.S District Court of Eastern Louisiana. -
Louisiana Xarelto Lawsuit Claims Anticoagulant Caused Fatal Bleeding And Subsequent Death Of Grandmother
Feb 3, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) in relation to the blood-thinning drug they manufacture, Xarelto. The lawsuit was filed by a granddaughter on behalf of her grandmother who died after suffering health complications while taking Xarelto. She was prescribed the drug by her physician in September of 2014 to treat her deep vein thrombosis (DVT) condition. Only two months later, however, she suddenly suffered an intracranial bleed. Doctors termed the bleed as “irreversible and fatal,” and it ultimately cost the woman her life. -
Xarelto Lawsuit Alleges Drug Caused Severe Gastrointestinal Bleed For Resident Of NJ
Feb 4, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit filed on November 23, 2015, against Xarelto manufacturersBayer AG and Janssen Pharmaceuticals discussing potential dangers of the blood thinning drug. The suit was filed by a New Jersey resident who claims that the manufacturers (and Janssen’s parent company, Johnson & Johnson) neglected to sufficiently warn consumers about the alleged dangerous and potentially fatal bleeding side effects he has come to link to it. -
Xarelto Lawsuit Plaintiffs Allege Studies On Anticoagulant Were Not Properly Managed And Are Unreliable
Feb 5, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Bayer Healthcare and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation). The lawsuit discusses their blood-thinning drug Xarelto and alleges that these manufacturers failed to adequately warn consumers of the dangerous bleeding episodes which have been linked to it. It additionally claims that the studies that advertisements and prestigious medical journals relied on were improperly managed and, therefore, unreliable. This particular lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana under case number 2:15-cv-04273. -
Xarelto Lawsuit From Ohio Woman Alleges Drug Caused Her Severe Gastrointestinal Bleed
Feb 5, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of corporate giant Johnson & Johnson), the manufacturers of blood-thinning drug Xarelto. The plaintiff, in this case, is an Ohio woman who alleges that the anticoagulant caused her to suffer a dangerous gastrointestinal bleed, leaving her with a need for longer-term medical care due to the damaging side effects she has sustained. -
Xarelto Lawsuits Show No Sign of Stopping
Jan 29, 2016 | LawyersandSettlements.com
By Heidi Turner
New Orleans, LAXarelto lawsuits alleging patients suffered severe bleeding events after using the anticoagulant drug show no signs of stopping, with 2,400 lawsuits now sitting in the multidistrict litigation for pretrial proceedings. Plaintiffs say they were not warned Xarelto had no antidote and were not warned about the risks of a serious bleeding event while taking Xarelto. -
Xarelto Bleeding
Jan 30, 2016 | Schmidt National Law Group
According to Xarelto monograph, most common among Xarelto side effects are Xarelto bleeding complications (1). However, several types of Xarelto bleedings may threaten a patient’s health and, in some circumstances, even his or her life. Some Xarelto bleedings can be in fact obviously manifest like Xarelto gum bleeding or Xarelto hemorrhoidal bleeding, while some other hidden ones like Xarelto Gastrointestinal bleeding and Xarelto hematomas can be much more subtle and dangerous indeed. Let’s give a look to all the Xarelto bleedings to know more about them. -
Xarelto Lawsuit Lawyer
Jan 31, 2016 | Rosenbaum & Rosenbaum, P.C.
When someone is at risk of a stroke because of an irregular heartbeat, there are a couple of medication options. One is Xarelto, marketed by Bayer. It's a drug that is supposed to prevent blood clot-related strokes by thinning the blood. But Xarelto is also associated with raising the risk of internal bleeding - internal bleeding so severe that it can be fatal. Has this happened in your family? If so, the law firm of Rosenbaum & Rosenbaum, P.C., can help you understand your legal rights and seek appropriate compensation. Our lawyers serve clients throughout the New York City area and have ample experience bringing defective drug cases forward. -
January Recap: 400 new Xarelto lawsuits filed in just one month
Feb 1, 2016 | Schmidt National Law Group
By xareltolawsuits.net
The number of US citizens that’s seeking the help of a Xarelto lawyer to bring their cases in court is growing to unprecedented levels. Since New Year’s eve, more than 400 Xarelto lawsuits have been added to the already large amount of other cases that form the Xarelto Multidistrict Litigation (MDL number 2592) in New Orleans. The large Xarelto MDL now includes almost 3,000 Xarelto injury lawsuits that will be held before U.S. District Honourable Judge Eldon E. Fallon, in addition to the 500 cases of the Philadelphia, PA Xarelto Mass Tort. -
Lawsuit: Xarelto Failed to Prevent Ischemic Stroke
Feb 2, 2016 | Top Class Actions
By Paul Tassin
Amid hundreds of Xarelto lawsuits alleging the anticoagulant medication caused excessive bleeding, a man from Florida now claims that Xarelto failed to prevent his ischemic stroke. -
New Xarelto Investigation Could Be Costly
Feb 2, 2016 | Drug Lawsuit Source
Drug regulators in the United States are investigating whether a defective blood clotting test altered results of a trial involving Xarelto, one of Bayer’s best selling pharmaceutical products. The primary concern is whether Bayer (European manufacturer of Xarelto) and Johnson & Johnson (U.S. manufacturer of Xarelto) exaggerated Xarelto’s claims and benefits for stabilizing heartbeats. Currently, Xarelto is being used to prevent strokes in elderly patients with irregular heartbeats. -
Ohio Xarelto Lawsuit
Feb 2, 2016 | Ohio Injury Attorney Group
Blood clots can be life-threatening, which is why many medical professionals prescribe blood-thinning medication for preventative treatment. A recently released anticoagulant drug on the market today, Xarelto, is claimed by manufacturers to be a replacement for older treatment options such as Warfarin. However, the drug has become the focus of numerous lawsuits, with patients alleging complications from the drug ranging from uncontrollable bleeding to death. An Ohio Xarelto lawsuit maybe an option for patients who have suffered uncontrollable bleeding or other complications after taking Xarelto. -
Xarelto Bleeding Lawsuits See Continued Increase Of Filings In Federal And State Courts
Feb 2, 2016 | Southern Med Law
As parties in the Xarelto litigation prepare cases for trial, about 3,400 Xarelto bleeding lawsuits have been filed in state and federal courts. The Xarelto lawsuits are filed against Bayer HealthCare and Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit, on behalf of patients who commonly allege they suffered serious bleeding events, including brain bleeds and gastrointestinal hemorrhages. Some plaintiffs required hospitalization for transfusions. Survivors of Xarelto users have also filed claims alleging their loved ones suffered a fatal episode of Xarelto bleeding. -
Xarelto Lawsuit 1
Feb 3, 2016 | Medical Assistance Group
Xarelto is a drug used as an anticoagulant, or blood-thinner. In July 2011, it was approved by the U.S. Food and Drug Administration. Since that time, sales have grown steadily as it was being used as an alternative to the well-established blood-thinning drug Warfarin. Xarelto, along with other similar drugs have fallen under rising controversy and a growing number of lawsuits. -
Xarelto Lawsuit Says Blood Thinner Caused Gastrointestinal Bleed
Feb 3, 2016 | Top Class Actions
By Laura Schultz
A new Xarelto lawsuit was recently filed alleging that Janssen Pharmaceuticals violated consumer protection laws and put consumers at risk of suffering from dangerous gastrointestinal bleeds. -
Xarelto Lawsuit Information
Feb 4, 2016 | Schmidt National Law Group
The blood-thinner Xarelto can cause uncontrolled bleeding, a dangerous side effect that can cause severe injuries and even death. -
Xarelto Caused Gastrointestinal Bleed, Lawsuit Says
Feb 5, 2016 | Top Class Actions
By Paul Tassin
A woman from North Carolina has joined the multidistrict litigation over Xarelto alleging the anticoagulant medication caused her gastrointestinal bleed.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
-
Xarelto Lawsuit Study Published By BMJ Indicates Possible Twofold Increased Risk Of GI Bleeds
Feb 1, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
February 01, 2016 – /PressAdvantage/ – BloodThinnerHelp.com reports on studies published in the British Medical Journal which link the use of anticoagulant Xarelto to an increased risk for specific dangerous bleeding events, such as spontaneous vitreous hemorrhages (eye bleeds) and gastrointestinal bleeds. As lawsuit numbers surrounding the drug continue to increase on a regular basis, and the concerns of the plaintiffs involved have been made public, people across the nation are beginning to discuss some very serious side effects which have now been connected to the drug by multiple tests.
As additional information from these studies has been published, the public has become understandably concerned about the results they see. Plaintiffs involved in the lawsuits share even more concern as they point to studies which were made public in the summer of 2015. The studies appear to highlight additional concerning information about the blood thinner and its side effects.
A study which was published by JAMA Ophthalmology on June 25th of 2015 indicated that researchers had linked the use of rivaroxaban (the generic form of Xarelto) to an elevated risk of spontaneous vitreous hemorrhage, or bleeding of the eyes. Researchers involved noted, “The risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants simultaneously.”
When Xarelto first launched onto the market as a revolutionary new-generation blood thinner, many people switched from traditional blood thinners to try it. This warning especially concerns these individuals. Today as well, many consumers continue to transition from traditional blood thinners to Xarelto. Plaintiffs note that although studies now show a concerning link here, manufacturers of the drug, Bayer AG and Janssen Pharmaceuticals, have failed to properly release adequate safety warning information to the public and keep them aware of these new links; a problem that plaintiffs indicate has cost some Xarelto users their lives.
Another study concerning the anticoagulant was published in BMJ in April of 2015. This study evaluated thousands of blood thinner patients across the nation, following their product use and medical outcomes. The study indicated that consumers who used Xarelto (rivaroxaban) may be potentially doubling their risk of suffering from gastrointestinal bleeds as those who take warfarin. The researchers in this study noted, “…we cannot rule out…a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin.”
Plaintiffs involved in lawsuits which allege these health issues and more are currently awaiting fair trials. Over 2,800 federally-filed cases have been consolidated by the JPML to form MDL no. 2592. At this time, these consolidated cases are being overseen by Judge Eldon E. Fallon.
Attorney Joseph Osborne understands the potentially devastating effects of dangerous bleeding episodes. He is currently working to provide assistance to those who have not yet filed Xarelto lawsuits, but who have suffered from health issues that they link to the drug. These individuals deserve the opportunity to fully explore their legal rights, and may be entitled to substantial compensation. To better provide these individuals assistance as they pursue justice, Attorney Osborne is currently offering free consultations for qualifying parties.
To request additional information on Xarelto lawsuits, or ask questions, please contact attorney Joseph Osborne by calling (866) 425-8902.
http://www.wave3.com/story/31113872/xarelto-lawsuit-study-published-by-bmj-indicates-possible-twofold-increased-risk-of-gi-bleeds
-
A Silent Killer: Raise Your Blood Clot Awareness to Reduce Your Risks
Feb 1, 2016 | HealthNewsDigest.com
By Quentin Danziger
(HealthNewsDigest.com) - Blood clots are a subject that too many of us don't discuss in great detail if at all, and this means that there is not always the level of awareness needed about this silent killer.
There are numerous situations which could cause you to develop a blood clot and sometimes it is not a lack of awareness but negligence that leads to this serious or fatal situation developing. If you have been affected and feel there is a claim to pursue, you can find xarelto lawsuit information at xlawsuit.com.
It is important to gain an understanding of what causes blood clots and how you might be able to reduce your risk of suffering from Deep Vein Thrombosis.
Blood clots can help and hinder
The job your blood does on a continual basis is quite impressive and its aim is to flow smoothly and efficiently throughout your body at all times, but it also needs to be able to shut off at the point where you are cut or injured in order to prevent excessive loss.
It should be appreciated that blood clots are actually a help as well as a hindrance.
They can be viewed as a great help when they work to stop excessive bleeding and damaging blood loss but blood clots can also form when they are neither wanted or required, which can subsequently lead to a heart attack, stroke or some other serious medical issue that could threaten your life.
The cause of blood clots
A blood clot will start to form when your flowing blood makes contact with certain substances in your skin in the blood vessel walls.
If this occurs, it is often a sign that the skin or blood vessel wall has been punctured. Blood can also be known to form when you have a problem with the blood in your body flowing as it should. Slowly moving blood can cause clotting problems and atrial fibrillation and deep vein thrombosis (DVT) are two examples of conditions that can develop as a result of blood clots.
Most heart attacks are triggered by the waxy cholesterol plaques that form in your arteries breaking open, which is a situation your body reacts to by starting the clotting process. This sudden bursting of the plaque in your heart or brain is one of the most common causes of a heart attack.
DVT
If you have any existing knowledge of deep vein thrombosis, it is probably advice you have seen regarding spending a long time on a plane and the potential damage it can do by causing swelling in your legs.
DVT occurs as a result of a blood clot forming in one of the deep veins of your body. It most commonly affects your legs but you can also develop DVT in your arms as well.
The danger signs of DVT include a noticeable swelling in one leg or arm in particular. Tenderness or leg pain that feels like a bad bout of cramp, or you notice that your skin has a slightly red or blue discoloration and your leg or arm is warmer than usual to touch.
If you have any of these symptoms, you should not hesitate to contact your doctor or seek medical attention, as DVT requires treating as soon as possible.
Further complications
A serious complication which can be fatal, is when the clot breaks off from a DVT and makes its way to the lung.
This scenario can result in causing a pulmonary embolism (PE).
The main signs and symptoms associated with PE include a sharp or stabbing pain in your chest, which feels worse when you take deeper breaths. You might also experience a rapid heart rate and a sudden unexplained shortness of breath or a cough which produces a bloody mucus.
Any of these PE symptoms can result in fatal consequences so you are advised to call 911 immediately if you have reasonable cause to suspect that this is what is wrong with you.
It is often best not to be cautious about these symptoms, when you consider that roughly 100,000 American's die each year from blood clots and that is a rate of about one in three of every person who develops a clot.
Understanding what causes blood clots and what symptoms to look out for can prove to be a real lifesaver, so make sure you do what you can to reduce the risk of this happening to you.
Quentin Danziger has a Bachelor of Science in Engineering Physics from Colorado School of Mines. 10 year Owner/Operator of a successful offline business in Vail, Colorado
http://www.healthnewsdigest.com/news/News_10/A-Silent-Killer-Raise-Your-Blood-Clot-Awareness-to-Reduce-Your-Risks.shtml
-
Feb 1, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
February 01, 2016 – /PressAdvantage/ – BloodThinnerhelp.com reports on several studies pointing to data that appears to support plaintiffs arguments and raise more questions over the safety of new-generation anticoagulant drug Xarelto. The blood thinner is manufactured by Bayer Healthcare and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation). These new studies highlight a potential link to spontaneous and severe bleeding episodes, including stomach bleeds and eye-hemorrhages for patients using Xarelto.
The first of two notable studies was completed by Doctors John C. Hwang and Judy H. Hun after they had observed certain problems experienced by patients in their practice involving those aged 70-89 who initially used traditional blood thinner warfarin, and had later switched to use new-generation blood thinner Xarelto. The doctors noticed that these individuals were increasingly suffering from vitreous hemorrhages, or eye bleeds. Further testing confirmed to the medical team that when patients switched blood thinners, they were at increased risk for this health issue to occur.
The doctors carefully documented full medical evaluations of patients as they started to wean off of warfarin and begin Xarelto, and this is when they witnessed the most eye bleeding incidents. Their full reports on the bleeding events were published by JAMA Ophthalmology in their June, 2015 issue. As evaluated patients began to wean off of their traditional blood thinner (Warfarin), and switch over to Xarelto, this is when the bleeding incidences would occur. The doctor’s reports stated: “In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated.” They were hopeful that their discoveries would prevent other patients from switching blood thinners and experiencing the same problem.
Another study that also lends support to current Xarelto lawsuit plaintiffs, was published in an April 2015 issue of BMJ. This study indicated researchers of the different types of blood thinners were unable to rule out as much as a twofold increased risk of stomach bleeding for those taking Xarelto when compared to those using Warfarin. This study evaluated the results of almost 46,000 patients to come to these conclusions.
If these results are in fact accurate, they greatly support the arguments of almost 2,800 plaintiffs who have filed lawsuits against Xarelto manufacturers alleging that the blood thinner caused them dangerous and uncontrollable bleeding episodes, and, in some cases, that these episodes were fatal. Federally filed Xarelto lawsuits have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) to form MDL No. 2592. They are being overseen by Judge Eldon Fallon in New Orleans, Louisiana.
Today, Attorney Joseph Osborne is working to help ensure that everyone who has taken Xarelto and who has also suffered from serious side effects will have the opportunity to evaluate their full legal rights. It is possible for additional lawsuits to join the current MDL as the cases await further legal proceedings. Attorney Osborne is now offering free Xarelto consultations to affected individuals, who may be entitled to substantial compensation.
To ask questions or request further information on Xarelto lawsuits, please contact Attorney Osborne by calling (866) 425-8902.
http://www.keyc.com/story/31113700/xarelto-lawsuit-plaintiffs-gain-support-from-jama-ophthalmology-study-results-linking-drug-to-dangerous-bleeds
-
Xarelto Lawsuit Claims Drug Manufacturers Hold Liability For Wife’s Life-Threatening Injuries
Feb 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit which was filed against manufacturers Bayer AG and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson corporation). The lawsuit, filed by a couple from Ohio, alleges that their anticoagulant drug, Xarelto, caused the wife to suffer dangerous, life-threatening internal bleeding injuries. Together, the husband and wife have requested more than $150,000 compensation to help with their current medical bills, future medical bills, and pain and suffering.
Court documentation shares details which indicate that the plaintiff was prescribed Xarelto (rivaroxaban) by her family doctor to treat a common heart condition known as atrial fibrillation, which can put people at increased risk for strokes. In order to prevent her from suffering a stroke, the doctor suggested that she take the blood thinner.
After only two months of Xarelto use, the woman suddenly experienced a serious gastrointestinal bleed and anemia, as well as multiple other injuries. According to the plaintiffs, she still requires medical care today for injuries sustained from these episodes.
The U.S. Food and Drug Administration (FDA) approved Xarelto as a new-generation blood thinner. It was approved to reduce the risk of blood clot formation in individuals recovering from hip and knee replacement surgeries, as well as reducing stroke risks in those with atrial fibrillation.
Today, Xarelto is the topic of over 3,000 lawsuits filed across the United States, which similarly claim that the drug puts those taking it at increased risk of spontaneous uncontrollable bleeding episodes, some of which are potentially fatal. Over 2,800 of these cases have been consolidated to form multidistrict litigation No. 2952 by the U.S. Judicial Panel on Multidistrict Litigation. These cases are being overseen in New Orleans, Louisiana. In addition to these federally filed cases, there is a group of another 550 Xarelto lawsuits which have been consolidated to form a mass tort group in Philadelphia, Pennsylvania.
As the many lawsuit plaintiffs await justice through a fair trial, many anticipate that other cases will continue to appear. Attorney Joseph Osborne is now working to assist those who were negatively affected by Xarelto but who have not yet filed their own lawsuits. These individuals may be entitled to substantial compensation. Involved individuals are encouraged to fully explore their legal opportunities. Attorney Osborne is currently offering free legal consultations to affected persons.
To request further information or ask questions about Xarelto lawsuits, contact Joseph Osborne, Esq., by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2821336#ixzz3z1pAvyVk -
Xarelto Lawsuit Surge Creates Public Concern Over Blood Thinner’s Once-Daily Dosage
Feb 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an especially notable lawsuit filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer Healthcare in a Pennsylvania State Court. This lawsuit is important to observe because thousands of Xarelto lawsuits have been filed against these manufacturers regarding the uncontrollable bleeding dangers associated with the anticoagulant, however, this one brings up a new concern: the one pill per day dosage of the the new-generation blood thinner.
Xarelto happens to be the only blood thinner on the market today that offers a one pill per day dose. Most blood thinners require 2 pills per day to ensure that the body is properly medicated for an entire 24-hour period. The specific complaints found within this suit state that the drug’s recommended once-daily dose is ineffective for an entire 24-hour period of time. The plaintiff involved notes that he believes this to be the case as he suddenly suffered from a stroke just four days after starting Xarelto specifically in an attempt to prevent strokes, which he was at increased risk for because of a heart condition called atrial fibrillation.
Xarelto’s dose is not only one pill per day, that pill is also considered a one-size-fits-all dosage. No matter the size of the patient using Xarelto, the dosage remains the same. After suffering from his stroke, the plaintiff filed a lawsuit on October 8, 2015 against the anticoagulant’s manufacturers. His lawsuit is the first of its type, and has gained much public attention and raised additional new questions about the product. In addition to alleging that Xarelto neglected to prevent his stroke, the man involved indicates that the drug may have even caused it.
Nationally, Xarelto has been the subject of more than 2,800 lawsuits filed in federal court and over 550 suits which were consolidated to form a mass tort group in the Court of Common Pleas in Philadelphia, Pennsylvania. In 2011, the blood thinner was approved by the U.S. Food and Drug Administration to prevent strokes and blood clots for those recovering from certain surgeries such as hip and knee replacements, and this use was later expanded to include treating patients with atrial fibrillation.
When Xarelto was initially released to the market as a new-generation blood thinner, many consumers were intrigued. The new drug was marketed heavily, and plaintiffs allege that the marketing misleadingly focused on the benefits of the drug rather than adequately addressing its potential dangerous side effects. Xarelto was given two black box warnings by the U.S. Food and Drug Administration. These warnings are the most strict and severe warnings a product can get before being pulled from the market.
Plaintiffs who federally-filed Xarelto-related lawsuits have seen their cases consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592. These lawsuits are being overseen by Judge Eldon E. Fallon. As the plaintiffs involved in these cases await their own personal justice, Attorney Joseph Osborne is attempting to ensure that anyone suffering after using Xarelto will be given the opportunity to fully explore their legal rights. He is currently offering complimentary consultations to affected individuals, who may be entitled to legal action and substantial compensation.
Read more: http://www.digitaljournal.com/pr/2823341#ixzz3zD76SmAS
-
Feb 2, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an investigation reviewing clinical trials of Xarelto by European regulators. This investigation follows a surge of lawsuits which have been filed against the blood thinner’s manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation). The plaintiffs involved in these mounting lawsuits commonly allege that use of the new-generation blood thinner can cause consumers increased risks of dangerous uncontrollable bleeding events.
A clinical trial has now been placed under investigation by European regulators. Initially, the trial was completed at the Duke Institute for Clinical Research. Reports from the Project on Government Oversight seem to indicate that the official who issued the U.S. FDA’s 2011 approval of Xarelto had discussed some concerns over the drug as well. POGO stated, “The FDA approved Xarelto in 2011 over the objections of the primary FDA scientists assigned to study its safety and effectiveness. The report by the reviewers argued that patients could be ‘at greater risk of harm from stroke and/or bleeding’ if they took Xarelto than if they were treated skillfully with Warfarin, a blood thinner that has been on the market since the 1950’s.”
In addition to these statements, POGO also noted, “The official who issued the FDA’s decision to approve the drug expressed a series of misgivings about it.” This individual, FDA Deputy Division Director Stephen M. Grant said, “The decision was made difficult by the limitations in the design and conduct” during the clinical trial. He noted this in a memo from November of 2011.
Today, the anticoagulant has been named in over 2,800 federally filed lawsuits which were consolidated by the JPML to form multidistrict litigation No. 2592 in one court in the Eastern District of Louisiana. The cases are currently being presided over by Judge Eldon Fallon, and continue to grow in number. They are additionally joined by another 550 cases which were consolidated to form a mass tort group in Philadelphia, Pennsylvania. Since its initial release to market, the FDA has given Xarelto two black box warnings, which are the most serious product warnings possible before it is removed from the market.
AllGov.org also discussed additional details of the European review of Xarelto’s clinical trial, noting, “The clinical trial relied on blood testing devices that were the subject of two FDA warning letters before the trial began and an FDA recall notice after the trial ended, according to the Project on Government Oversight (POGO). Certain devices in the INRatio product line, the warning notice read, could deliver false test results and use of those devices may “cause severe or life-threatening injuries, including death.”
Newly emerging information has indicated that the EMA “is currently investigating whether the data generated from the INRatio device could have had any impact on the trial results and the extent of this impact, if applicable.” In November, POGO also reported that an FDA staff review of the clinical trial in question indicated that the trial appeared to be biased in favor of the approval of Xarelto. These indications will continue to progress and plaintiffs currently involved in Xarelto lawsuits look forward to their results.
Attorney Joseph Osborne is currently working to make sure that everyone who has been negatively affected by Xarelto will have the opportunity to fully evaluate their legal rights. These people may be entitled to substantial compensation. To help those deserving of justice, Attorney Osborne is offering complimentary legal consultations to affected individuals.
To learn more about Xarelto litigation, or to ask questions, contact Joseph Osborne, Esq. (866) 425-8902.
http://www.digitaljournal.com/pr/2822999#ixzz3z254NMAw
-
Xarelto Lawsuit Plaintiffs Are Encouraged By Similarities To Previously Settled Pradaxa Cases
Feb 2, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on similarities between today’s Xarelto lawsuits and previously settled Pradaxa lawsuits, which bring comfort to plaintiffs awaiting Xarelto trials and seeking what they consider to be justice. Xarelto lawsuit numbers continue to regularly increase as the many cases await trial. All Xarelto cases filed in federal courts from across the nation were consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML). These cases now make up MDL No. 2592 in New Orleans, and are said to involve over 2,800 lawsuits.
The MDL cases for Xarelto are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana. The complaints of all cases have been filed against two defendants: Janssen Pharmaceuticals, (a division of the Johnson & Johnson corporation), and Bayer AG. In addition to these nearly 3,000 cases, another 550 Xarelto bleeding lawsuits have been consolidated to form a mass tort group by the Court of Common Pleas in Philadelphia, Pennsylvania.
Orders given by the Honorable Judge Fallon requested that by January 11th of 2016, 40 bellwether cases be selected to form a bellwether pool from which 4 cases will be chosen to head to representative trials. The judge requested that 10 of the 40 cases be chosen by plaintiffs and 10 of the 40 be chosen by defendants, with the remaining 20 cases to be chosen by the court. As of now, it is expected that these bellwether trials will be heard in the Spring of 2017.
All lawsuits filed against the manufacturers of blood-thinning drug Xarelto similarly claim that it can cause uncontrollable bleeding episodes, both internally or externally, which can prove dangerous or even fatal. A frequent point of contention discussed by lawsuit plaintiffs is that Xarelto manufacturers released their anticoagulant to the public without any accompanying antidote for emergency situations; a decision that plaintiffs call recklessly negligent.
Without an available antidote, if a patient who has taken Xarelto becomes injured and bleeds, doctors may be unable to clot the blood and stop the bleed. These situations call for extreme life-saving measures such as surgeries to drain pools of blood, and blood transfusions. Even a minor bleeding injury can quickly turn into a dangerous and life-threatening situation when someone’s blood cannot clot.
Manufactured by Boehringer Ingelheim in 2010, Pradaxa, like Xarelto, was considered a “new-generation” blood thinner. Within only a short time after its public launch, Pradaxa was the subject of over 3,500 reports of dangerous health complications, more than 750 of which were noted to be fatal. Soon, the drug manufacturers were facing over 4,000 lawsuits regarding their blood thinner. One day prior to trials for these lawsuits, however, Boehringer Ingelheim paid $650 million to plaintiffs in order to settle the suits.
Today, Xarelto plaintiffs find hope in these results. Attorney Joseph Osborne is currently working to ensure that everyone who may have been negatively affected by Xarelto will have the opportunity to fully explore their legal rights. At this time, he is offering free legal consultations to affected individuals. It is believed that those affected may be entitled to legal action and substantial compensation.
To request further information, or ask questions regarding Xarelto bleeding lawsuits, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2820009#ixzz3z1pjeP3z -
Feb 3, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) in relation to the blood-thinning drug they manufacture, Xarelto. The lawsuit was filed by a granddaughter on behalf of her grandmother who died after suffering health complications while taking Xarelto. She was prescribed the drug by her physician in September of 2014 to treat her deep vein thrombosis (DVT) condition. Only two months later, however, she suddenly suffered an intracranial bleed. Doctors termed the bleed as “irreversible and fatal,” and it ultimately cost the woman her life.
Details found within court documents for this lawsuit show that the plaintiff alleges that Xarelto caused her grandmother’s fatal bleed and, while physicians attempted to keep the woman alive, significant pain, mental anguish, and unpayable medical bills also resulted. The granddaughter states that while considering blood thinners, she and her grandmother had observed several advertisements which heavily promoted Xarelto without properly addressing any serious bleeding risks, which many plaintiffs now link to the blood thinner. The plaintiff also stated that the defendant’s marketing tactics “overstated the efficacy of Xarelto with respect to preventing stroke and systemic embolism.”
This lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana under number 2:15-cv-05874. It has been consolidated there with other Xarelto lawsuits to form multidistrict litigation number 2592. Federal cases included in this MDL now number over 2,800, while another 550 lawsuits concerning Xarelto have been consolidated to form a mass tort group in Philadelphia, Pennsylvania. Cases in the Louisiana MDL are being overseen by the Honorable Judge Eldon Fallon, and all commonly allege that Xarelto can cause a number of sudden, serious, and even fatal bleeding incidents.
Attorney Joseph Osborne is now working to ensure that anyone who may have suffered adverse health effects after taking Xarelto but who has not yet filed suit will have the opportunity to at least evaluate their legal rights. These individuals may be entitled to significant compensation. To help encourage those deserving to pursue justice, Attorney Osborne is currently offering free legal consultations for affected parties.
http://www.digitaljournal.com/pr/2825122#ixzz3zD6ejYV3
-
Xarelto Lawsuit Numbers Now Surpass 3,000 Across The United States And Share Concerning Allegations
Feb 3, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on recent Xarelto lawsuit news, which indicates that cases filed against Janssen Pharmaceuticals and Bayer AG in relation to blood-thinning drug Xarelto have now surpassed 3,000 in number. A group of over 2,800 Xarelto lawsuits has been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592 in Louisiana while another group of 550 Xarelto lawsuits has been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania to form a mass tort group.
The mounting lawsuits share similar allegations which state that defendants neglected to properly warn the public about an alleged increased risk for uncontrollable bleeding episodes for those taking the anticoagulant. The Xarelto lawsuits similarly mirror Pradaxa lawsuits which also numbered in the thousands, and recently settled out of court. Plaintiffs are continuously stepping forward with new lawsuits and allegations about the dangers of the drug, and many feel that case numbers will only continue to increase as current plaintiffs await further trial preparations.
Xarelto was approved by the U.S. Food and Drug Administration to help treat individuals recovering from hip and knee replacement surgeries who might be at risk of blood clots or stroke. Additionally, this approved use was expanded to include treatment of patients with a common heart condition termed atrial fibrillation. This condition also puts patients at increased risk of stroke.
Reports from across the U.S. have claimed a link between Xarelto use and strokes as well as spontaneous eye and stomach bleeds and uncontrollable bleeding episodes in general, some of which have proven fatal. Xarelto’s one-pill-per-day recommended dosage has also been met with recent scrutiny, as all other blood thinners require two doses of medication daily for adequate protection.
As these lawsuits continue to grow in number, Attorney Joseph Osborne has been working to ensure that anyone who may have been negatively affected by the drug, but who has not yet filed suit, will have the opportunity to explore that option. These individuals are believed to potentially be entitled to substantial compensation. To help encourage the pursuit of justice, Attorney Osborne is currently offering free legal consultations for involved parties.
To request additional information on Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
-
Xarelto Lawsuit Plaintiffs Note Bellwether Trial Preparations In Louisiana MDL Number 2592
Feb 3, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the bellwether trial preparations of over 2,800 federally-filed Xarelto lawsuits which were consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592. The lawsuits which have been consolidated name the same defendants and commonly allege that Xarelto puts users at increased risk for dangerous uncontrollable bleeding episodes, which, in some cases, plaintiffs claim have been fatal. These cases continue to progress toward trial dates at this time and are centralized in the U.S District Court of Eastern Louisiana.
http://www.foxcarolina.com/story/31135324/xarelto-lawsuit-plaintiffs-note-bellwether-trial-preparations-in-louisiana-mdl-number-2592#ixzz3zD8UwjRb
-
Feb 3, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) in relation to the blood-thinning drug they manufacture, Xarelto. The lawsuit was filed by a granddaughter on behalf of her grandmother who died after suffering health complications while taking Xarelto. She was prescribed the drug by her physician in September of 2014 to treat her deep vein thrombosis (DVT) condition. Only two months later, however, she suddenly suffered an intracranial bleed. Doctors termed the bleed as “irreversible and fatal,” and it ultimately cost the woman her life.
Details found within court documents for this lawsuit show that the plaintiff alleges that Xarelto caused her grandmother’s fatal bleed and, while physicians attempted to keep the woman alive, significant pain, mental anguish, and unpayable medical bills also resulted. The granddaughter states that while considering blood thinners, she and her grandmother had observed several advertisements which heavily promoted Xarelto without properly addressing any serious bleeding risks, which many plaintiffs now link to the blood thinner. The plaintiff also stated that the defendant’s marketing tactics “overstated the efficacy of Xarelto with respect to preventing stroke and systemic embolism.”
This lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana under number 2:15-cv-05874. It has been consolidated there with other Xarelto lawsuits to form multidistrict litigation number 2592. Federal cases included in this MDL now number over 2,800, while another 550 lawsuits concerning Xarelto have been consolidated to form a mass tort group in Philadelphia, Pennsylvania. Cases in the Louisiana MDL are being overseen by the HonorableJudge Eldon Fallon, and all commonly allege that Xarelto can cause a number of sudden, serious, and even fatal bleeding incidents.
Attorney Joseph Osborne is now working to ensure that anyone who may have suffered adverse health effects after taking Xarelto but who has not yet filed suit will have the opportunity to at least evaluate their legal rights. These individuals may be entitled to significant compensation. To help encourage those deserving to pursue justice, Attorney Osborne is currently offering free legal consultations for affected parties.
http://www.newschannel10.com/story/31135348/louisiana-xarelto-lawsuit-claims-anticoagulant-caused-fatal-bleeding-and-subsequent-death-of-grandmother
-
Xarelto Lawsuit Alleges Drug Caused Severe Gastrointestinal Bleed For Resident Of NJ
Feb 4, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit filed on November 23, 2015, against Xarelto manufacturersBayer AG and Janssen Pharmaceuticals discussing potential dangers of the blood thinning drug. The suit was filed by a New Jersey resident who claims that the manufacturers (and Janssen’s parent company, Johnson & Johnson) neglected to sufficiently warn consumers about the alleged dangerous and potentially fatal bleeding side effects he has come to link to it. His lawsuit was filed under case number 2:15-cv-06264 in the U.S. District Court for the Eastern District of Louisiana, where over 2,800 other similar cases have been consolidated.
The consolidation was ordered by the U.S. Judicial Panel on Multidistrict Litigation due to the similarities of the claims and the fact that all lawsuits were filed against the same defendants. The cases now form multidistrict litigation number 2592 and cases are being overseen in New Orleans by Judge Eldon Fallon. Most recently, they have undergone bellwether trial preparations, and involved plaintiffs look forward to hearings currently set for the beginning of 2017.
These mounting federal court cases are not the only ones, however. Another set of lawsuits concerning the dangers of anticoagulant Xarelto has formed a mass tort group of more than 550 cases in Philadelphia, Pennsylvania. These cases were consolidated by the Philadelphia Court of Common Pleas. Although these consolidations have taken place, the lawsuits have continued to steadily grow in number and are expected to continue to increase as they await trial.
Details of this particular lawsuit are found in court documents and state that after just six months of Xarelto use, the plaintiff suddenly suffered from what doctors termed a life-threatening gastrointestinal bleed. With the Xarelto in his system, and no available antidote at the time of his bleed, doctors had to depend on emergency life-saving treatments in order to keep the man alive and stop him from losing too much blood. Although he is happy to be alive, the plaintiff claims he will continue to suffer with medical issues for the rest of his life due to this occurrence.
Attorney Joseph Osborne is currently working to ensure that everyone who has suffered from bleeding episodes after using blood thinning drug Xarelto will be offered the opportunity to explore their legal rights fully. These consumers may be entitled to significant compensation. To help better support their pursuit of justice, Attorney Osborne is offering free consultations for affected individuals at this time.
To ask questions or request additional information, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2826681
-
Feb 5, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Bayer Healthcare and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation). The lawsuit discusses their blood-thinning drug Xarelto and alleges that these manufacturers failed to adequately warn consumers of the dangerous bleeding episodes which have been linked to it. It additionally claims that the studies that advertisements and prestigious medical journals relied on were improperly managed and, therefore, unreliable. This particular lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana under case number 2:15-cv-04273.
When it was first released to the market for public purchase, many considered Xarelto to be a revolutionary new generation blood thinner. Xarelto was the only blood thinner on the market to offer just one pill per day dosage for everyone. Today, some question the effectiveness of this one pill, which is supposed to last an entire 24-hours. The drug was approved by the FDA to treat patients just recovering from hip or knee replacement surgeries, in order to help prevent the development of blood clots. It was also intended to prevent the development of deep vein thrombosis (DVT) and pulmonary embolism. Later, the drug was additionally approved to help prevent stroke for people suffering from atrial fibrillation (a common heart condition).
Plaintiffs involved in the mounting lawsuits surrounding the drug have indicated that in important medical journals from across the nation, Xarelto is the most predominantly advertised drug. Many plaintiffs claim that the manufacturer’s advertising was misleading and primarily focused on benefits of the drug, rather than properly addressing the negatives. These journals have the important job of keeping the medical community aware of newly emerging medical trends and advancements.
Together, the plaintiffs involved in this case allege that Xarelto manufacturers have intentionally concealed the great dangers their anticoagulant may pose to consumers, including fatal ones. Several of the plaintiffs from across the nation who are involved in current Xarelto lawsuits are representing loved ones who have passed away from serious bleeding episodes while using the drug. In this specific lawsuit, plaintiffs note that throughout the United States and Germany, thousands of “adverse events” have now been reported in connection with Xarelto.
Xarelto lawsuits now number over 2,800 cases in federal court. They have been consolidated to form MDL No. 2592 and are currently being overseen in the Eastern District of Louisiana by Judge Eldon Fallon. Additionally, in Philadelphia, Pennsylvania, the Court of Common Pleas has consolidated over 550 Xarelto cases to form a mass tort group. As these many lawsuit plaintiffs await further preparations for trial, many expect that both groups will only continue to grow in number.
At this time, Attorney Joseph Osborne is working to help ensure that everyone who has been negatively affected by Xarelto will be given the opportunity to fully evaluate their legal rights. These people may be entitled to legal action and therefore substantial compensation. Patients who have used the blood thinner and have suffered from adverse health events are now being offered free legal consultations.
To ask questions or request additional information, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2823513
-
Xarelto Lawsuit From Ohio Woman Alleges Drug Caused Her Severe Gastrointestinal Bleed
Feb 5, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of corporate giant Johnson & Johnson), the manufacturers of blood-thinning drug Xarelto. The plaintiff, in this case, is an Ohio woman who alleges that the anticoagulant caused her to suffer a dangerous gastrointestinal bleed, leaving her with a need for longer-term medical care due to the damaging side effects she has sustained.
The plaintiff noted in lawsuit details that she was prescribed Xarelto by her physician in order to treat her atrial fibrillation condition. Atrial fibrillation is a heart condition which is common but can put people suffering from it at an increased risk of stroke. Blood thinners are often prescribed in these cases as a preventative measure to help discourage the occurrence of a stroke. Although the woman did not have a stroke while on Xarelto, she alleges that she suffered an event equally as serious.
The plaintiff claims that she had been using the drug under one year’s time when she suffered from a spontaneous and severe gastrointestinal bleeding episode. Xarelto has been repeatedly linked to these types of dangerous uncontrollable bleeding episodes, both external and internal, by plaintiffs from across the nation, and in multiple studies as well. In some cases, the bleeds become fatal and caused the death of the patients involved. In this case, the plaintiff survived but now alleges that the occurrence has left her with medical needs that will be long term.
The U.S. Food and Drug Administration (FDA) approved Xarelto in 2011. The FDA approved the anticoagulant to treat patients who had undergone hip and knee replacement surgeries, or who are at risk of developing deep vein thrombosis (DVT), and to prevent blood clots and strokes. A bit later, the FDA also expanded the drug’s approved uses to include treatment for atrial fibrillation patients.
When Xarelto first came onto the market as a new-generation blood thinner, it was commonly thought of as revolutionary. Suddenly a blood thinner was available which required no regular monitoring or dosage adjustments by physicians. It also offered a convenient one pill per day dosage. Today, plaintiffs question all of these things. Some allege that one pill does not adequately protect someone taking it for a full 24-hour period; others say that the drug should require monitoring and that the lack of monitoring was part of the problem. All plaintiffs commonly agree that the defendants used misleading marketing tactics which focused on the benefits of the drug and neglected to properly communicate the many dangers associated with it.
At this time, Attorney Joseph Osborne is working to ensure that anyone who has suffered from an adverse health event after using Xarelto will have the opportunity to fully explore their legal options. Affected parties may be entitled to legal action and substantial compensation. Attorney Osborne also currently offers free legal consultations for those who qualify, to help them in their pursuit of justice.
To obtain additional Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2827638
-
Xarelto Lawsuits Show No Sign of Stopping
Jan 29, 2016 | LawyersandSettlements.com
By Heidi Turner
New Orleans, LA-Xarelto lawsuits alleging patients suffered severe bleeding events after using the anticoagulant drug show no signs of stopping, with 2,400 lawsuits now sitting in the multidistrict litigation for pretrial proceedings. Plaintiffs say they were not warned Xarelto had no antidote and were not warned about the risks of a serious bleeding event while taking Xarelto.
According to reports from the Judicial Panel for Multidistrict Litigation (JPML), as of December 15, 2015, there were 2,400 lawsuits consolidated for pretrial proceedings in MDL 2592 (In Re: Xarelto (Rivaroxaban) Products Liability Litigation, before US District Judge Eldon E. Fallon). Although the growth of the MDL has slowed down somewhat from October, there is still a significant number of lawsuits added to the MDL monthly. As of November 16, 2015, there were 2,266 lawsuits consolidated, which was up from the 1,698 lawsuits consolidated by mid-October.
Lawsuits allege patients were not warned that Xarelto, unlike Coumadin, did not have an antidote to the drug’s anticlotting mechanism. Xarelto is an anticoagulant, used to reduce the risk of blood clots and strokes. But it, like its predecessor Coumadin, is associated with an increased risk of serious bleeding events due to its anticlotting properties.
Coumadin, which has been on the market for decades, has an antidote in the form of vitamin K. Patients who experienced a bleeding event and received medical attention in time could end the bleeding event. But patients on newer anticoagulants - including Xarelto - currently have no accepted antidote. That means if they experience a bleeding event, they have to wait for the drug to leave their system. Plaintiffs say if they had known about the lack of an antidote, they would not have used Xarelto.
The first bellwether trials in the Xarelto litigation are not expected to go to court until early 2017. In a case management order (11/30/15), Judge Fallon noted that the two sides could not resolve differences concerning discovery pool plaintiffs and bellwether trial plaintiffs, and issued orders regarding how cases could be selected for inclusion in the discovery pool. The judge further noted that four cases will be selected as bellwether cases but did not issue an order on selecting bellwether trial cases.Xarelto’s maker, Janssen Pharmaceuticals, maintains the drug is not unreasonably dangerous and the drug’s warnings are adequate.
https://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-32-21159.html
-
Jan 30, 2016 | Schmidt National Law Group
According to Xarelto monograph, most common among Xarelto side effects are Xarelto bleeding complications (1). However, several types of Xarelto bleedings may threaten a patient’s health and, in some circumstances, even his or her life. Some Xarelto bleedings can be in fact obviously manifest like Xarelto gum bleeding or Xarelto hemorrhoidal bleeding, while some other hidden ones like Xarelto Gastrointestinal bleeding and Xarelto hematomas can be much more subtle and dangerous indeed. Let’s give a look to all the Xarelto bleedings to know more about them.
Xarelto Brain Bleeding
A Xarelto brain bleeding is a type of stroke caused by a vessel bursting and leaking blood within the brain. This bleeding can prevent adequate blood flow, reducing local perfusion and causing cells in nearby areas of the brain to die. It also irritates the area, causing a swelling known as “edema.” As soon as fluids start accumulating, and blood collects into a mass called hematoma, pressure on nearby tissues increases, further preventing adequate blood supply from reaching cells. Xarelto brain bleeding cannot be seen from the outside unless the patient receives a CT scan, but some symptoms can be associated with this condition (2, 3). Principal Xarelto brain bleeding symptoms include:Unusual and/or severe headachesLack of balance and coordinationSeizuresNumbnessWeakness on one side of the bodyDifficulty speaking or understanding speechNausea or Vomiting
Xarelto Gastrointestinal Bleeding
Xarelto Gastrointestinal bleeding (GI bleeding) is one of the most common forms of Xarelto hidden bleeding. Several studies pointed out how GI bleeding is more frequent in patients treated with Xarelto than those treated with Warfarin. Xarelto Gastrointestinal bleeding rates were, in fact, 42% higher than Warfarin GI hemorrhage rates, and tend to be more frequent and severe among older patients aged 75 years or over (4, 5). Xarelto gastrointestinal bleeding risk is higher when patients are prescribed other anticoagulants such as antiplatelet agents or nonsteroidal anti-inflammatory drugs (NSAIDs) (6).
Xarelto Gastrointestinal bleeding can be so small that only lab tests can detect it, but still be threatening because of the long-term effects of blood loss. Gastrointestinal hemorrhages can happen in any tract of the digestive tract including the esophagus, stomach, small intestine, colon, rectum, and anus. Xarelto hemorrhoidal bleeding are included in this category, as lower gastrointestinal tract hemorrhages. Hemorrhoids can ben painful or painless, depending whether they become swollen and inflamed or not. Constipation and increased abdominal pressure can be the cause of hemorrhoids, and always represent detrimental factors to their development. Xarelto hemorrhoidal bleeding can be concerning and usually require additional examination to fully evaluate them. Profuse Xarelto hemorrhoidal bleeding which can’t be stopped may require emergency treatment (7).
Symptoms of Xarelto gastrointestinal hemorrhage include:Bright red blood in vomitVomit that looks like coffee groundsBlack or tarry stool, or covered with bright red bloodPain and irritation around the anal areaUnusual headachesConstant fatigue and/or dizzinessPale skin
Other Xarelto Hidden Bleeding
One forms of Xarelto hidden bleeding include all kind of small injuries and trauma which can lead to internal bleeding. Even a simple accident like a fall can be very dangerous while under treatment with Xarelto. Basic Xarelto precautions are of paramount importance for any patient who wishes to avoid ending in emergency room, and even small bruises should never be underestimated. Xarelto internal bleeding caused by trauma can be very severe, and the lack of a proper reversal agent further endangers a patient’s health whenever this kind of accidents do happen (8). Xarelto hidden bleedings can also happen under the skin or scalp, manifesting themselves as small blisters or unusual skin folding. Patients under Xarelto treatment should always be wary about sport injuries and other forms of internal bleeding including:BruisesFallingBlunt traumaJoint painBack, legs or abdominal painUnusually dry skinBlisters or Skin foldingBlood in the urines
Xarelto External Bleeding
Xarelto external bleeding include all kind of bleedings caused by cuts and perforations. Even holding a knife can be dangerous while under Xarelto treatment, as the lack of a Xarelto antidote prevents doctors from stopping the bleeding. Immediate application of a firm, direct pressure on the wound can help staunch the bleeding. However, due to the anticoagulant action of the medication you may need to press for a longer time than usual before the bleeding stops.If bleeding does not stop after a while, you should check immediate help. Even minor bleeding accidents such as Xarelto nosebleed or Xarelto gum bleeding should never be underestimated. Try to avoid forceful nose blowing, and buy a tootbrush with soft bristles to reduce the chance of Xarelto gum bleeding. The most common forms of Xarelto external bleeding include:Xarelto Gum BleedingXarelto Nose BleedingXarelto Skin Bleeding
Xarelto Menstrual Bleeding
For women taking Xarelto, experiencing longer or heavier menstrual bleedings is a common side effect. However, Xarelto menstrual bleeding can also represent a risk that should be addressed immediately. If you experience menstrual bleeding that is heavier than normal, you should call your doctor or seek medical help as soon as possible. Xarelto vaginal bleeding can also be caused by external traumas or during normal sex intercourse (1).
https://xareltolawsuits.net/xarelto-bleeding/
-
Jan 31, 2016 | Rosenbaum & Rosenbaum, P.C.
Holding Drug Companies Accountable For Harm Caused By Xarelto
When someone is at risk of a stroke because of an irregular heartbeat, there are a couple of medication options.
One is Xarelto, marketed by Bayer. It's a drug that is supposed to prevent blood clot-related strokes by thinning the blood. But Xarelto is also associated with raising the risk of internal bleeding - internal bleeding so severe that it can be fatal.
Has this happened in your family? If so, the law firm of Rosenbaum & Rosenbaum, P.C., can help you understand your legal rights and seek appropriate compensation. Our lawyers serve clients throughout the New York City area and have ample experience bringingdefective drug cases forward.The Choice Between Rivaroxaban And Warfarin
You probably trusted your doctor when agreeing to use Xarelto (also known as rivaroxaban). But your doctor may not have known the risks because both the maker and the manufacturer of Xarelto failed to disclose them. That failure to disclose or warn is galling.
It is especially galling given that there is an older drug that may be an effective alternative to Xarelto, one that doesn't carry such risks of internal bleeding. That drug is warfarin.
There is a lot of controversy concerning assertions made by Bayer about Xarelto's effectiveness. The U.S. Food and Drug Administration (FDA) is looking into the validity of various test results on Xarelto.
Xarelto is Bayer's top-selling drug, and the temptation to try to skew the research findings is undeniable. Xarelto has earned more than 3 billion euros in the past two years for Bayer, a German company.Signs and Symptoms Of Trouble
Severe internal bleeding isn't the only potential risk associated with Xarelto. It can also cause deficient hemoglobin levels, swelling, general weakness, confusion and other problems.
Obviously you will want to get these checked out by a competent doctor. If your trust in your doctor is not what it once was, that is understandable. But it isn't necessarily your doctor's fault that the makers of Xarelto didn't provide sufficient warnings of the possibility of serious harm.People Are More Important Than Profits
Making money - even big money - doesn't justify a drug company's failure to disclose undue health risks that may have badly harmed your family. Give us a call today to discuss your specific situation with an attorney in a no-cost consultation. Call 646-475-3665 or 800-724-7971 or complete our online form.
http://www.rosenbaumnylaw.com/Defective-Drugs/Xarelto.shtml
-
January Recap: 400 new Xarelto lawsuits filed in just one month
Feb 1, 2016 | Schmidt National Law Group
By xareltolawsuits.net
The number of US citizens that’s seeking the help of a Xarelto lawyer to bring their cases in court is growing to unprecedented levels. Since New Year’s eve, more than 400 Xarelto lawsuits have been added to the already large amount of other cases that form the Xarelto Multidistrict Litigation (MDL number 2592) in New Orleans. The large Xarelto MDL now includes almost 3,000 Xarelto injury lawsuits that will be held before U.S. District Honourable Judge Eldon E. Fallon, in addition to the 500 cases of the Philadelphia, PA Xarelto Mass Tort.
Plaintiffs and their Xarelto Attorneys accuse Janssen Pharmaceuticals and Bayer AG of not adequately warning them about the risks associated with the use of the blood thinner. Xarelto side effects did, in fact, include severe bleedings that in some circumstances even led patients to death. As no Xarelto antidote has ever been approved, even the smallest Xarelto uncontrollable bleeding accident can prove to be fatal, and for this reason, many families are now filing Xarelto bleeding lawsuits to ask for proper compensation.
Plaintiffs’ claims are very similar to those alleged in the previously settled Pradaxa litigation. Patients blame the pharmaceutical companies of holding precious information about the drug’s purported safety, as well as being negligent in warning the public of its dangerous side effects. Pradaxa was manufactured by Boehringer Ingelheim in 2010, just one year before Xarelto was released to the market. Similarly to Xarelto lawsuits, Pradaxa lawsuits reached a total of over 4,000 cases, and the pharmaceutical company agreed to pay $650 million to settle down the accusations. Xarelto lawyers hope for a similar solution and are encouraging patients who suffered any type of harm caused by Xarelto uncontrollable bleedings, to file a Xarelto lawsuit before the time limit is over.
This large number of litigations led Xarelto Attorneys to be very positive about the potential outcome of this trial. The number of cases increased from 2,400 to 2,800 in just one month, with an almost +20% net growth that will probably keep increasing in the upcoming months. -
Lawsuit: Xarelto Failed to Prevent Ischemic Stroke
Feb 2, 2016 | Top Class Actions
By Paul Tassin
The plaintiff says he suffered an ischemic stroke after taking Xarelto to prevent stroke related to his atrial fibrillation. He claims that the once-a-day dosing schedule recommended for Xarelto was inadequate to prevent stroke.
Xarelto is drug maker Janssen Pharmaceuticals’ brand name for the drug known generically as rivaroxaban. It’s been on the market since the FDA first approved it for sale in 2011. Xarelto is now approved for use in preventing stroke and systemic embolism in patients with atrial fibrillation. It’s also used to prevent and treat pulmonary embolism and deep vein thrombosis.
Xarelto is one of three new medications that recently challenged warfarin’s decades-long prominence in the market for anticoagulant drugs. Since the 1950s, warfarin (also known by the brand name Coumadin) was the most frequently prescribed anticoagulant medication, and it was the only drug approved to prevent stroke in patients with atrial fibrillation.
However, warfarin has its drawbacks. Treatment with warfarin requires the patient to undergo regular blood testing to ensure that the dosage is correct: too little warfarin will fail to prevent stroke, and too much puts the patient at risk for excessive bleeding.
The new generation of anticoagulants like Xarelto were designed and marketed to be taken without regular blood testing. Xarelto itself was also designed to be taken only once a day, to make treatment simpler and more convenient. However, some Xarelto lawsuit plaintiffs take issue with that once-a-day dosing schedule, alleging that more frequent dosing would be safer.
Xarelto and Ischemic Stroke
The plaintiff from Florida is not the only patient to have suffered an ischemic stroke simultaneous with Xarelto treatment. A case study published in the October 2014 issue of the Austin Journal of Pharmacology and Therapeutics details the story of one 88-year-old woman who suffered an acute ischemic stroke while taking rivaroxaban.
The woman had been hospitalized twelve days for sudden weight loss. During that time she continued to take rivaroxaban, which she had been taking to prevent stroke associated with her atrial fibrillation.
Just before she was discharged, the woman began to have slurred speech and weakness in her left arm and left leg. She was diagnosed with acute ischemic stroke and transferred to a specialized vascular institute.
After four days of treatment for her stroke, she was transferred back to the first facility. But since treatment with rivaroxaban had failed to prevent her stroke, her providers discontinued that medication and started her on a different anticoagulant drug.
The Xarelto MDL
Legal claims over Xarelto side effects have already begun stacking up. About 1,700 Xarelto lawsuits are already pending in a multidistrict litigation in a Louisiana federal court.
Generally, the plaintiffs in this MDL allege that Xarelto caused them cerebral hemorrhage, gastrointestinal bleeding, or other types of excessive bleeding that were in some cases life-threatening or actually fatal. These plaintiffs allege that Janssen Pharmaceuticals and other defendants failed to properly warn physicians and their patients about the risk of Xarelto bleeding.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/304959-plaintiff-says-xarelto-failed-to-prevent-ischemic-stroke/
-
New Xarelto Investigation Could Be Costly
Feb 2, 2016 | Drug Lawsuit Source
Drug regulators in the United States are investigating whether a defective blood clotting test altered results of a trial involving Xarelto, one of Bayer’s best selling pharmaceutical products. The primary concern is whether Bayer (European manufacturer of Xarelto) and Johnson & Johnson (U.S. manufacturer of Xarelto)exaggerated Xarelto’s claims and benefits for stabilizing heartbeats. Currently, Xarelto is being used to prevent strokes in elderly patients with irregular heartbeats.
In the original trial, a particular device known as the INRatio may have possibly skewed the results of a drug testing comparison of Xarelto and Warfarin. The use of this device may have created the appearance that Xarelto responded superiorly to other tested drugs as a result of a faulty device used in the trial. Over 2,000 lawsuits have been filed throughout the United States, alleging some fatalities and other injuries, including uncontrollable bleeding from patients prescribed Xarelto.
While this new investigation remains ongoing, it is critical that you speak with an experienced and knowledgeable attorney if you believe that you or a loved one was injured by the ingestion of Xarelto. In fact, many of the symptoms that result from the ingestion of a harmful pharmaceutical drug may take weeks if not months to materialize. Upon discovering any adverse new condition, seek medical assistance promptly in order to obtain the correct diagnosis. Claims against pharmaceutical companies can be expensive and time-consuming. Selecting an attorney that is knowledgeable in lawsuits against major pharmaceutical companies is critical to prevailing on a claim.
Our Xarelto Drug Lawyers Can Help
Our Xarelto drug attorneys can help if you or someone you care about was harmed by the prescription or ingestion of Xarelto. Lawsuits have been filed against the manufacturer by both patients and their families seeking compensation for injuries caused by the dangerous drug. You may be entitled to a settlement.
Our No Fee Promise on Xarelto Drug Cases
You can afford to have our great team of lawyers on your side. When you choose us, it literally costs nothing to get started. We promise you in writing:No money to get started We pay all case costs and expenses No legal fees involved (unless you receive a settlement)
Phone calls are always free Start Your Xarelto Drug Claim
http://www.druglawsuitsource.com/new-xarelto-investigation-could-be-costly/
-
Feb 2, 2016 | Ohio Injury Attorney Group
Blood clots can be life-threatening, which is why many medical professionals prescribe blood-thinning medication for preventative treatment. A recently released anticoagulant drug on the market today, Xarelto, is claimed by manufacturers to be a replacement for older treatment options such as Warfarin. However, the drug has become the focus of numerous lawsuits, with patients alleging complications from the drug ranging from uncontrollable bleeding to death. An Ohio Xarelto lawsuit maybe an option for patients who have suffered uncontrollable bleeding or other complications after taking Xarelto.
If you or a loved one suffered severe complications after taking Xarelto, contact the Ohio Injury Attorney Group to learn more about your options. We offer free, confidential, no obligation consultations. We can help answer your questions, and if you have a case we can connect you with an affiliated Xarelto lawsuit attorney in Ohio.
Important: The time you have to pursue a claim is limited. Contact us for more information.Why Is Xarelto Prescribed?
There are several conditions in which the risk of developing blood clots is increased. Xarelto is most commonly prescribed in patients who have recently undergone surgery for hip and knee replacements, as well as those suffering from atrial fibrillation, a condition in which blood can pool in the heart, where it then begins to clot. Xarelto is a member of a class of anticoagulants known as direct thrombin inhibitors. These medications prevent blood clots from forming in the body, which can then travel to the heart, lungs or brain, resulting in deep vein thrombosis, pulmonary embolism or stroke.
Xarelto, was manufactured by Bayer AG and Janssen Pharmaceuticals as a replacement for another common blood-thinning medication, Warfarin. As an alternative, Xarelto was advertised as superior to Warfarin, since blood monitoring was allegedly not required while taking the medication, and doctors supposedly do not have to alter dosages.
For patients with atrial fibrillation, the medication is designed to reduce the risk of strokes caused by clots that are formed due to an irregular heartbeat. The U.S. Food and Drug Administration (FDA) also approved the use of Xarelto for patients who have had hip or knee replacement surgery, since these patients are at a higher risk of developing blood clots that may lead to a pulmonary embolism.Xarelto Side Effects
The most dangerous potential side effect of Xarelto is uncontrollable internal bleeding. This is also a side effect in other anticoagulants, however with Xarelto, there was no antidote at the time the drug was introduced that could be used to flush the drug out of the system in order to stop the bleeding. As a result, there was an increased complication for physicians to treat patients suffering from complications that were connected to the medication. There are also reports that Xarelto may actually increase the risk of blood clots in some patients, especially those taking the drug after knee or hip replacement surgery.
Other side effects and complications of Xarelto include:Abdominal bleedingReduced platelet levelsAbnormal liver functionBrain hemorrhaging
According to court records, the FDA has received over 2,000 reports of severe side effects from Xarelto patients, approximately 1,800 of which list Xarelto as the suspected cause. The deaths of approximately 183 patients have been linked to Xarelto in reports submitted to the FDA.Ohio Xarelto Lawsuit
Although there are currently no class action suits for Xarelto, there has been a multidistrict litigation started that had nearly 2200 cases related to the drug as of November 2015. Many of these lawsuits, which allege injury or even death related to the taking of the drug, claim that the manufacturers knowingly downplayed the risks of Xarelto and marketed it as a beneficial anticoagulant alternative, despite knowing that it could cause uncontrollable bleeding.
As there is usually a statute of limitations on when you can file a claim, it is important that you consult with an Ohio Xarelto lawsuit attorney to find out what your options are.Injured Patients May Be Entitled to Compensation
Drug manufacturers have a duty to ensure their products are accompanied by full and accurate instructions and warnings to guide prescribing doctors and other health care providers in making treatment decisions. If a drug maker fails to fulfill this duty, it could be held liable in lawsuits for injuries that may result.
Patients who have been injured by Xarelto may be entitled to compensation for damages, including:Medical expensesPain, suffering, and mental anguishLoss of income or ability to work
If a patient dies from complications after taking Xarelto, his or her family members may be able to pursue claims for their loved one’s wrongful death. Compensation may include:Pain, suffering, and mental anguish from the loss of a loved oneLoss of financial support of a loved oneFuneral expenses
Affected patients are encouraged to speak with an Ohio Xarelto lawsuit attorney to learn more about their rights and remedies.Contact Us For More Information
If you or a loved one took Xarelto and suffered complications, including internal bleeding, contact the Ohio Injury Attorney Group for more information. You can fill out the form on this page, call us at the number listed at the top of the page, or email us at info@attorneygroup.com.
When you contact us, an attorney will follow up with you to speak with you about your case or answer questions that you might have. There is no cost or obligation to speak with us, and any information you provide will be kept confidential.
Please note that the law limits the time you have to pursue a claim for an injury. If you think you have a case, you should not delay taking action.
See our Frequently Asked Questions page for more information, and contact the Ohio Injury Attorney Group today.
https://attorneygroup.com/ohio/lawsuits/bad-drugs/xarelto/
-
Xarelto Bleeding Lawsuits See Continued Increase Of Filings In Federal And State Courts
Feb 2, 2016 | Southern Med Law
As parties in the Xarelto litigation prepare cases for trial, about 3,400Xarelto bleeding lawsuits have been filed in state and federal courts. The Xarelto lawsuits are filed against Bayer HealthCare and Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit, on behalf of patients who commonly allege they suffered serious bleeding events, including brain bleeds and gastrointestinal hemorrhages. Some plaintiffs required hospitalization for transfusions. Survivors of Xarelto users have also filed claims alleging their loved ones suffered a fatal episode of Xarelto bleeding.
As of January 15, 2,826 Xarelto bleeding complaints have been filed in the U.S. District Court, Eastern District of Louisiana, where all federally filed Xarelto lawsuits have been consolidated for pretrial proceedings. An additional 574 Xarelto cases are pending in a mass tort proceeding in the Philadelphia Court of Common Pleas in Pennsylvania. Attorneys for the plaintiffs and defendants in both state and federal litigations are in the discovery process which requires the parties to exchange information on cases that could potentially go to trial. (In Re: Xarelto Products Liability Litigation, No. 2592) (In Re: Xarelto Litigation, Case ID 150102349)
“At the same time as Xarelto cases increase in the state and federal litigations, our law firm continues to receive inquiries from people who have been prescribed Xarelto and have experienced severe bleeding events that have devastated their lives,” says Dr. François Blaudeau, founder of Southern Med Law.
As both an attorney and practicing physician, Southern Med Law’s Dr. François Blaudeau possesses a unique understanding of the medical and legal questions relating to Xarelto lawsuits. If you or a loved one experienced life-threatening internal bleeding or other complications allegedly associated with Xarelto, please contact Southern Med Law as soon as possible to learn more about your legal rights. You can arrange for a free, no obligation Xarelto lawsuit review by calling Southern Med Law today, at 205-547-5525.
Xarelto is a blood thinner approved by the U.S. Food and Drug Administration (FDA) to prevent strokes, deep vein thrombosis, pulmonary embolism, and blood clots in patients with atrial fibrillation, not caused by a heart valve problem. After its initial approval in 2011, Xarelto went on to garner $2 billion in sales nationwide with roughly 1 million prescriptions written by 2013, according to the petition to create a Xarelto mass tort in the Philadelphia court. The FDA considers Xarelto a new-generation blood thinner compared to warfarin, a blood thinner that has been on the U.S. market since 1954. While Xarelto is more popular with patients because regular blood monitoring is not required like it is with warfarin, Xarelto does not have an approved antidote to treat internal bleeding side effects. Warfarin uses vitamin K as an antidote for bleeding events, according to the FDA.
Xarelto lawsuit claims filed in state and federal litigation commonly allege that the defendants knew or should have known that Xarelto has dangerous side effects. One Xarelto lawsuit recently filed in the federal litigation contended the plaintiff suffered personal injuries because the defendants did not disclose the risks associated with Xarelto. The New Jersey woman took Xarelto from November 2013 to April 2014. On March 11, 2014, and again on April 2, 2014, the woman suffered a gastrointestinal bleed allegedly as a result of using Xarelto, according to the complaint. (Case No.2:15-cv-07120, U.S. District Court, Eastern District of Louisiana)
About Southern Med Law and Filing A Xarelto Bleeding Lawsuit: Throughout his career, Dr. Blaudeau has worked hard to develop a strong reputation in healthcare litigation. His first-hand knowledge of medicine has made the Southern Med Law team aggressive and effective legal representatives for those who were harmed due to negligent pharmaceutical companies. If you or a loved one were harmed by Xarelto, please contact Southern Med Law today to learn more about your legal rights. Call today for a free, no obligation Xarelto lawsuit review by filling out our online form, or by calling the office directly at 205-547-5525.
https://www.southernmedlaw.com/2637-2/2637
-
Feb 3, 2016 | Medical Assistance Group
Risks of Xarelto Use
Xarelto is a drug used as an anticoagulant, or blood-thinner. In July 2011, it was approved by the U.S. Food andDrug Administration. Since that time, sales have grown steadily as it was being used as an alternative to the well-established blood-thinning drug Warfarin. Xarelto, along with other similar drugs have fallen under rising controversy and a growing number of lawsuits.
Xarelto Initially Approved
Initially Xarelto was approved for the use of patients recovering from hip and knee replacement surgery. When recovering from these types of surgeries, patients run a risk of deep vein thrombosis (blood clots in legs). Approval uses have grown since that time. To reduce risk of strokes, patients which have an irregular heartbeat, also known as atrial fibrillation, have been prescribed Xarelto. This drug is used for treatment of patients that develop blood clots in their lungs, or pulmonary embolisms.
Risk with Use
There may be a risk that is increased for patients taking blood thinners for heart attack, stroke, deep vein thrombosis, and pulmonary embolism. Majority of patients taking prescription blood thinners like Xarelto are already vulnerable to serious health issues as these.
When taking blood thinning medications such as Xarelto, patients are at an increased risk of injuries related to bleeding. Most common is hemorrhaging and gastrointestinal bleeding. After accidents or during surgery can lead to complications as well. What had caused the patient to take Xarelto to begin with, may now happen.
Xarelto Lawsuits
Many patients that have suffered from injuries which are bleeding-related, pulmonary embolisms, strokes, heart attacks, and deep vein thrombosis have sued. Leading reason is financial compensation. Injuries from Xareltocan be lengthy, long-term hospitalization, expensive costs for health care, and considerable amount of time away from work.
Legal Help
There are lawyers able to help patients recover financial compensation. They have knowledge navigating the legal system and are available if you call them.
http://www.medicalassistancegroup.com/2016/02/03/xarelto-lawsuit-1/
-
Xarelto Lawsuit Says Blood Thinner Caused Gastrointestinal Bleed
Feb 3, 2016 | Top Class Actions
By Laura Schultz
A new Xarelto lawsuit was recently filed alleging that Janssen Pharmaceuticals violated consumer protection laws and put consumers at risk of suffering from dangerous gastrointestinal bleeds.
The Xarelto lawsuit was brought by multiple plaintiffs against the Xarelto makers. One plaintiff, Theresa B. of New York, states she began taking Xarelto in January of 2012 after she was prescribed the medication by her doctor.
Theresa continued taking the medication until March 2012 when she began to experience a gastrointestinal bleed and discontinued the medication. The Xarelto lawsuit alleges that Teresa’s gastrointestinal bleed was a direct result of taking the blood thinner.
The Xarelto lawsuit alleges that the plaintiffs, including Theresa, suffered serious physical pain and suffering and incurred significant medical expenses. The plaintiffs are attempting to hold the drug manufacturers responsible for the injuries, pain, and suffering the drug caused them.
Xarelto and the other new anticoagulant medications on the market often credit themselves as being superior to the older blood thinning medications like warfarin. The Xarelto lawsuit brought by Theresa challenges these declarations.
According to the Xarelto lawsuit, a study known as the Rocket AF study compared warfarin to Xarelto and found the latter superior. But the lawsuit alleges the study was poorly managed. Theresa claims that the poor management of the project made Xarelto appear superior to warfarin. In the lawsuit, Dr. Steven Nissen stated his concern that the dosages for the trial study were picked for advertising purposes rather than scientific data.
What is Xarelto?
Xarelto is a popular anticoagulant sold on the market. The medication was manufactured, advertised, and distributed in order to treat people who are at risk for stroke and systemic embolism in patients who suffer from atrial fibrillation. Xarelto is also prescribed to treat deep vein thrombosis and pulmonary embolism in patients who have recently undergone hip or knee replacement surgeries.
Xarelto was introduced to the US market back in 2011. Xarelto and many of the other newer oral anticoagulants are often referred to as the next generation of blood thinners. The older blood thinners on the market, such as warfarin, require patients to undergo constant blood monitoring and a strict diet. According to Xarelto’s marketing, the blood thinning medication does not require patients to follow those same restrictions.
Xarelto Side Effects
Numerous FDA adverse event reports have been filed regarding Xarelto side effects although all blood thinning medications pose the risk of uncontrolled bleeding. In the first quarter of 2012, the FDA received over 120 Xarelto bleeding reports with patients, like Teresa, reportedly suffering from gastrointestinal bleeds, hemorrhaging, and several other serious internal bleeding complications.
The Xarelto Lawsuit is part of the Xarelto MDL known as In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592, in the U.S. District Court for the Eastern District of Louisiana.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/306866-ny-woman-files-xarelto-lawsuit-gastrointestinal-bleed/
-
Feb 4, 2016 | Schmidt National Law Group
Why you should file a Xarelto Lawsuit?Since Xarelto (rivaroxaban) received approval in 2011, Bayer AG and Janssen Pharmaceuticals (a Johnson & Johnson’s subsidiary) made millions by selling this Novel Oral Anticoagulant to US patients. Xarelto is used to prevent blood clots and strokes in people who suffer from Atrial Fibrillation (Afib), Pulmonary Embolism (PE), and Deep Vein Thrombosis (DVT). However, this drug is also very dangerous, as it may cause uncontrollable bleedings that cannot be stopped as there is no antidote available to reverse its effects.
Many people who were injured by Xarelto side effects, filed a lawsuit against the manufacture pharmaceutical companies Bayer, Johnson & Johnson’s and Janssen Pharmaceuticals, holding them accountable for the harm they suffered. Both Bayer and J&J, in fact, never warned patients properly about the medication’s risk. A lawsuit may be the only way to get compensation for all the damage sustained, including emotional injuries, the death of loved ones and financial loss. Plaintiffs principal accusations found in Xarelto lawsuits include negligence and failure to warn.
Why should you choose us as your Lawfirm?
For more than 50 years our lawyers at the Schmidt National Law Group have been consistently winning cases for their victims, granting them the rightful compensation for all their suffering. Our attorneys do really care about knowing a victims’ history. Every time a client asks for our help we know that there’s a tale of pain and suffering behind it. We know personally how heavy the burden of losing someone you love can be. Winning a lawsuit can help you cope with the financial draining caused by medical expenses, and most importantly, will ensure you will bring the pharmaceutical companies who harmed you to justice.
At the Schmidt National Law Group, we got all the experience required to stand up against even the largest corporations, and our skilled personal injury attorneys have passionately fought their legal battles to defend the rights of injured people for decades. We will answer to your call immediately, and we will provide you a legal consultation and help you evaluate your legal options for free.
https://xareltolawsuits.net/
-
Xarelto Caused Gastrointestinal Bleed, Lawsuit Says
Feb 5, 2016 | Top Class Actions
By Paul Tassin
A woman from North Carolina has joined the multidistrict litigation over Xarelto alleging the anticoagulant medication caused her gastrointestinal bleed.
Plaintiff Tandy B. says she took Xarelto for only two months, from October to November 2014. She stopped taking Xarelto around the time she suffered a gastrointestinal bleed. She now alleges that bleed was caused by the blood thinner.
Tandy is filing this Xarelto blood thinner lawsuit against Bayer Pharmaceuticals, Janssen Pharmaceuticals, and Janssen’s parent company Johnson & Johnson. Janssen is the division of J&J responsible for the manufacture, marketing and sales of Xarelto.
Xarelto, also known as rivaroxaban, is a relatively new anticoagulant medication. It has been on the market in the U.S. since first earning FDA approval in 2011.
Xarelto is frequently prescribed to prevent the risk of stroke and systemic embolism in persons with non-valvular atrial fibrillation. It’s also indicated for the treatment and prevention of pulmonary embolism and deep vein thrombosis.
Litigation Over Xarelto
The controversy over Xarelto originates in the risk that Xarelto treatment can lead to excessive bleeding. The same anticoagulant action that makes Xarelto prevent stroke and embolism also inhibits the body’s natural mechanism for slowing and stopping bleeding when it occurs.
This effect can put Xarelto patients at risk for dangerous conditions like a brain hemorrhage or, as in Tandy’s case, a gastrointestinal bleed. Some instances of excessive bleeding have ended in death.
Tandy’s Xarelto blood thinner lawsuit notes that in a set of clinical trials known as the RECORD studies, Xarelto showed more frequent instances of bleeding leading to decreased hemoglobin levels and requiring transfusions of blood.
The claim also cites a later set of trials known as the ROCKET AF study. Results from those trials showed that patients who took Xarelto had more frequent gastrointestinal bleeds.
Tandy is challenging the rationale behind Xarelto’s once a day dosing schedule. The defendants designed and made Xarelto to be taken once a day, making Xarelto treatment simpler and more convenient than treatment with competitor drugs.
However, Tandy cites comments by FDA clinical reviewers questioning the once a day schedule, noting that clinical pharmacology studies suggested that dosing twice a day would produce less variance in Xarelto blood levels. One clinical reviewer suggested that the once a day schedule was promoted more for a marketing advantage than for any clinically significant reason.
A report published by the Institute for Safe Medication Practices also questioned the once a day Xarelto dosing, saying that peaks and dips in the blood level of Xarelto would be better tempered by twice daily dosing.
Tandy also notes that in Xarelto’s first full year on the market, the FDA received no less than 2,081 reports of adverse events associated with Xarelto. Out of those reports, 151 ended in death, Tandy says. She also notes that in the first eight months of 2013, German regulators received 968 reports of Xarelto-related adverse events, 72 of which resulted in death.
Tandy’s Xarelto blood thinner lawsuit is part of the Xarelto multidistrict litigation now pending in the U.S. District Court for the Eastern District of Louisiana under MDL No. 2592.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/326737-xarelto-caused-gastrointestinal-bleed-plaintiff-says/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
Add recipients
Suggested